{"id":7834,"date":"2024-10-08T07:45:00","date_gmt":"2024-10-08T07:45:00","guid":{"rendered":"https:\/\/www.acarix.com\/multi-location-customer-places-order-of-the-acarix-cadscor-system-with-goal-to-scale-usage\/"},"modified":"2024-11-18T19:04:30","modified_gmt":"2024-11-18T19:04:30","slug":"multi-location-customer-places-order-of-the-acarix-cadscor-system-with-goal-to-scale-usage","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/multi-location-customer-places-order-of-the-acarix-cadscor-system-with-goal-to-scale-usage\/","title":{"rendered":"Multi-Location Customer Places Order of the Acarix CADScor System with Goal to Scale Usage"},"content":{"rendered":"
\n

Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce the sale of 9 CADScor Systems and 500 single-use patches to a prominent healthcare provider with 9 locations across 7 states in the US. This strategic purchase aims to establish the CADScor System as an integral part of their diagnostic workflow for assessing patients suspected of CAD.<\/strong><\/p>\n<\/div>\n

\n

With this initial acquisition, the healthcare provider has set a target to expand the usage of the system to at least 5 patches per day across each location.<\/p>\n

“This sale underscores the growing adoption of the CADScor System in multi-site healthcare operations,” said Aamir Mahmood, CEO of Acarix. “We are thrilled to support our customers in delivering better diagnostic solutions, and we look forward to working closely with them to achieve their goal of increasing daily patch usage.”<\/p>\n

Forward-Looking Statements:
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding expected performance and usage targets.<\/p>\n<\/div>\n

\n

For more information contact:<\/strong>
Jennifer Monies, phone +1 (405) 550-8144, jmonies@saxum.com<\/a><\/p>\n<\/div>\n

\n

About Acarix<\/strong><\/p>\n\n\n\n
Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

Attachments<\/strong>
Multi-Location Customer Places Order of the Acarix CADScor System with Goal to Scale Usage<\/a><\/p>\n<\/div>\n